INTRAVESICAL THERAPY FOR BLADDER CANCER

1 - 24 . (canceled)

25 . A method of therapy for bladder cancer in a bladder cancer patient comprising the instillation into the bladder of said patient of a composition comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies.

26 . The method according to claim 25 , wherein said composition comprises either anti-PD-L1 antibodies or anti-PD-1 antibodies.

27 . The method according to claim 25 , wherein said composition comprises anti-PD-L1 antibodies and anti-PD-1 antibodies.

28 . The method according to claim 25 , wherein said anti-PD-L1 antibody is MPDL3280A.

29 . The method according to claim 25 , wherein said anti-PD-1 antibody is pembrolizumab or nivolumab.

30 . The method according to claim 25 , wherein the composition comprises a therapeutically effective amount of anti-PD-L1 antibodies and/or anti-PD-1 antibodies.

31 . The method according to claim 25 , wherein the composition is a semi-solid composition or a liquid composition.

32 . The method according to claim 31 , wherein the composition is a liquid composition.

33 . The method according to claim 32 , wherein the composition comprises anti-PD-L1 antibodies and/or anti-PD-1 antibodies in a liquid carrier

34 . The method according to claim 33 , wherein the liquid carrier is water or an aqueous buffer.

35 . The method according to claim 31 , wherein the composition is a liquid composition comprising water, the pH of said composition is in the range of 4.5 to 7.5.

36 . The method according to claim 25 , wherein the composition is instilled into the bladder through a catheter and is left in the bladder from about 20 minutes to about 3 hours.

37 . The method according to claim 25 , wherein the composition further comprises hexyl 5-ALA ester or a pharmaceutically acceptable salt thereof and wherein after instillation of said composition into the bladder of said patient the inside of said bladder is exposed to light.

38 . The method according to claim 37 , wherein the concentration of hexyl 5-ALA ester in the composition is in the range of 0.1 to 5% by weight of the total weight of the composition or the equivalent concentration of a pharmaceutically acceptable salt of HAL.

39 . The method according to claim 38 , wherein the composition is a liquid composition obtained by reconstitution of lyophilized a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) lyophilized hexyl 5-ALA ester or a pharmaceutically acceptable salt thereof in a liquid carrier.

40 . The method according to claim 39 , wherein the liquid carrier is water or an aqueous buffer.

41 . The method according to claim 38 , wherein the composition is instilled into the bladder through a catheter and is left in the bladder from about 20 minutes to about 3 hours.

42 . The method according to claim 38 , wherein the inside of the bladder is exposed to white light and/or blue light and/or red light.

43 . The method according to claim 42 , wherein the inside of the bladder is exposed to white light followed by blue light.

44 . The method according to claim 25 , wherein said method is a neoadjuvant therapy for bladder cancer patients who are scheduled for a cystectomy or an adjuvant therapy for bladder cancer patients who undergo transurethral resection (TUR).

45 . The method according to claim 38 , wherein said method is a neoadjuvant therapy for bladder cancer patients who are scheduled for a cystectomy or an adjuvant therapy for bladder cancer patients who undergo transurethral resection (TUR).